CEO Nils Brünner comments: "We are very proud to receive this nomination which builds on Professor Tommy Anderssons innovative and cutting edge scientific work aimed to fight metastatic cancer. The challenge of helping cancer patients is the driving force for all employees at WntResearch. The nomination it is highly incentivizing for WntResearch and we greatly appreciate the nomination. I want to use this opportunity to thank all the people who have shown trust in WntResearch and thereby made it possible for us to continue the exciting clinical development of our lead product Foxy-5.” Please see: www.malmonaringslivsgala.se/2014/ For further information please contact: Nils Brünner, CEO Professor, MD, DMSc E-mail: nbr@wntresearch.com Telephone: +45 2614 4708 About WntResearch AB WntResearch (WNT.ST) is a public company listed at AktieTorget. WntResearch is developing novel anti-metastatic therapies for the treatment of cancer patients.